Honoring Dr. Saghari, the pioneer and enduring figure of Iran’s nuclear medicine, at the Conference of Specialists in Nuclear Medicine, Radiation Oncology, Hematology, and Oncology.

During the course of the “Conference of Specialists in Nuclear Medicine, Radiation Oncology, Hematology, and Oncology,” which was organized by Pars Isotope and hosted by Shohada-e Tajrish Hospital, Dr. Mohsen Saghari, a pioneer and enduring figure in the country’s nuclear medicine, was honored in recognition of his many years of scientific, educational, and professional service.

Mr. Mohammad Eslami, the Vice President and Head of the Atomic Energy Organization, along with a group of specialists in nuclear medicine, radiation oncology, hematology, and oncology, attended this ceremony. During the event, Dr. Saghari’s impactful role in the development of nuclear medicine, the training of multiple generations of physicians, and the advancement of novel diagnostic and therapeutic approaches based on radiopharmaceuticals was reviewed.

At this ceremony, emphasizing the role of pioneers in advancing medical sciences, the importance of transferring experience, knowledge, and scientific perspective across generations and its impact on improving the quality of cancer diagnosis and treatment was underscored.

Dr. Mohsen Saghari, a renowned figure in nuclear medicine, in his speech, spoke of the early years and the beginnings of nuclear medicine in the country, describing the progress of this modern medical field as remarkable. Expressing satisfaction with the current state of radiopharmaceutical production and the numerous nuclear medicine centers, he described this modern medical approach as fundamental and vital for controlling and treating cancer.

Subsequently, Mr. Mohammad Eslami, alongside the heads of the Nuclear Medicine, Radiation Oncology, Hematology, and Oncology associations, honored Dr. Saghari by presenting him with a certificate of appreciation.

The Conference of Specialists in Nuclear Medicine, Radiation Oncology, Hematology, and Oncology was held on December 25, with the aim of fostering synergy among related specialties, exchanging the latest scientific findings, and reviewing the future of radiopharmaceuticals in cancer treatment.